1,752
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

, , , &
Pages 951-961 | Accepted 07 May 2013, Published online: 07 Jun 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig & Leslie Citrome. (2018) Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research 10, pages 443-456.
Read now
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Ken O’Day, Krithika Rajagopalan, Kellie Meyer, Andrei Pikalov & Antony Loebel. (2013) Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. ClinicoEconomics and Outcomes Research 5, pages 459-470.
Read now

Articles from other publishers (7)

Rui Luo, He Lu & Hengfen Li. (2023) Cost-utility analysis of using paliperidone palmitate in schizophrenia in China. Frontiers in Pharmacology 14.
Crossref
Tom B. Mole, Yulia Furlong, Richard J. Clarke, Pradeep Rao, Julia K. Moore, Giulia Pace, Hugo Van Odyck & Wai Chen. (2021) Lurasidone for Adolescents With Complex Mental Disorders: A Case Series. Journal of Pharmacy Practice 35:5, pages 800-804.
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Mônica Kayo & Denise Razzouk. 2017. Mental Health Economics. Mental Health Economics 313 322 .
Krithika Rajagopalan, David Trueman, Lydia Crowe, Daniel Squirrell & Antony Loebel. (2016) Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics 34:7, pages 709-721.
Crossref
Anne Karow, Monika Bullinger & Martin Lambert. 2016. Beyond Assessment of Quality of Life in Schizophrenia. Beyond Assessment of Quality of Life in Schizophrenia 123 144 .
Mathieu Verdurand, Victoria S. Dalton, Vu Nguyen, Marie-Claude Grégoire, David Zahra, Naomi Wyatt, Leena Burgess, Ivan Greguric & Katerina Zavitsanou. (2014) Prenatal poly I:C age-dependently alters cannabinoid type 1 receptors in offspring: A longitudinal small animal PET study using [18F]MK-9470. Experimental Neurology 257, pages 162-169.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.